The Negative Impact of Maternal HIV Infection on Birth Outcomes-Myth or Reality?

Overview

Journal Pathogens

Date 2024 Sep 28

PMID 39338999

Authors

Tudor Fleseriu

Lorena Elena Melit

Cristina Oana Marginean

Anca-Meda Vasiesiu

Affiliations

Soon will be listed here.

Abstract

Human Immunodeficiency Virus (HIV) infection during pregnancy poses significant risks to both maternal and child health, with potential adverse effects on perinatal outcomes. This study aimed to compare perinatal outcomes, including birth weight, length, Apgar scores, and prematurity rates, between HIV-exposed, uninfected (HEU) children and HIV-unexposed, uninfected (HUU) children. A total of 204 neonates were included in the study, comprising 102 born to HIV-positive mothers and 102 born to uninfected mothers. Our findings revealed significant differences in birth weight ( < 0.001), length ( < 0.001), and Apgar scores at both 1 min ( = 0.003) and 5 min ( < 0.001) between HIV-exposed and -unexposed children. The HIV-exposed group exhibited lower birth weights and lengths, along with lower Apgar scores, indicating potential neonatal health challenges. No significant disparities were observed in the prematurity risk between the two groups (OR = 2.58, = 0.126), but the risk of being born small for gestational age (SGA) in the case of HEU newborns was significantly high (OR = 17.41, < 0.001). The significant differences in birth weight, length, and Apgar scores underscore the need for tailored healthcare interventions and support for neonates born to HIV-positive mothers. These findings contribute to our understanding of the complex interplay between maternal HIV infection and perinatal outcomes, guiding healthcare professionals in delivering targeted care for this vulnerable population.

References

Habib N, Daltveit A, Bergsjo P, Shao J, Oneko O, Lie R . Maternal HIV status and pregnancy outcomes in northeastern Tanzania: a registry-based study. BJOG. 2008; 115(5):616-24. DOI: 10.1111/j.1471-0528.2008.01672.x. View

Nachega J, Uthman O, Mofenson L, Anderson J, Kanters S, Renaud F . Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr. 2017; 76(1):1-12. PMC: 5553236. DOI: 10.1097/QAI.0000000000001359. View

McCormick M, Litt J, Smith V, Zupancic J . Prematurity: an overview and public health implications. Annu Rev Public Health. 2011; 32:367-79. DOI: 10.1146/annurev-publhealth-090810-182459. View

Papp E, Mohammadi H, Loutfy M, Yudin M, Murphy K, Walmsley S . HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis. 2014; 211(1):10-8. PMC: 4264589. DOI: 10.1093/infdis/jiu393. View

Zeitlin J, Szamotulska K, Drewniak N, Mohangoo A, Chalmers J, Sakkeus L . Preterm birth time trends in Europe: a study of 19 countries. BJOG. 2013; 120(11):1356-65. PMC: 4285908. DOI: 10.1111/1471-0528.12281. View

Mellqvist H, Saggers R, Elfvin A, Hentz E, Ballot D . The effects of exposure to HIV in neonates at a referral hospital in South Africa. BMC Pediatr. 2021; 21(1):485. PMC: 8565056. DOI: 10.1186/s12887-021-02969-6. View

Reitter A, Stucker A, Linde R, Konigs C, Knecht G, Herrmann E . Pregnancy complications in HIV-positive women: 11-year data from the Frankfurt HIV Cohort. HIV Med. 2014; 15(9):525-36. DOI: 10.1111/hiv.12142. View

von Moltke L, Greenblatt D, Grassi J, Granda B, Duan S, Fogelman S . Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998; 38(2):106-11. DOI: 10.1002/j.1552-4604.1998.tb04398.x. View

Sibiude J, Mandelbrot L, Blanche S, Chenadec J, Boullag-Bonnet N, Faye A . Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014; 11(4):e1001635. PMC: 4004551. DOI: 10.1371/journal.pmed.1001635. View

10.

Sauder M, Lee S, Schulze K, Christian P, Wu L, Khatry S . Inflammation throughout pregnancy and fetal growth restriction in rural Nepal. Epidemiol Infect. 2019; 147:e258. PMC: 6805761. DOI: 10.1017/S0950268819001493. View

11.

Uthman O, Nachega J, Anderson J, Kanters S, Mills E, Renaud F . Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV. 2016; 4(1):e21-e30. DOI: 10.1016/S2352-3018(16)30195-3. View

12.

Wedi C, Kirtley S, Hopewell S, Corrigan R, Kennedy S, Hemelaar J . Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. Lancet HIV. 2016; 3(1):e33-48. DOI: 10.1016/S2352-3018(15)00207-6. View

13.

Fiore S, Newell M, Trabattoni D, Thorne C, Gray L, Savasi V . Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol. 2006; 70(1-2):143-50. DOI: 10.1016/j.jri.2005.12.001. View

14.

Tukei V, Hoffman H, Greenberg L, Thabelo R, Nchephe M, Motsoane T . Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women. Pediatr Infect Dis J. 2021; 40(9):821-826. PMC: 8357042. DOI: 10.1097/INF.0000000000003174. View

15.

White M, Feucht U, Duffley E, Molokoane F, Durandt C, Cassol E . Does in utero HIV exposure and the early nutritional environment influence infant development and immune outcomes? Findings from a pilot study in Pretoria, South Africa. Pilot Feasibility Stud. 2020; 6(1):192. PMC: 7730756. DOI: 10.1186/s40814-020-00725-8. View

16.

Powderly W . Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr. 2002; 29 Suppl 1:S28-40. DOI: 10.1097/00126334-200202011-00005. View

17.

Vilanova C, Hirakata V, de Souza Buriol V, Nunes M, Goldani M, da Silva C . The relationship between the different low birth weight strata of newborns with infant mortality and the influence of the main health determinants in the extreme south of Brazil. Popul Health Metr. 2019; 17(1):15. PMC: 6882357. DOI: 10.1186/s12963-019-0195-7. View

18.

Kourtis A, Schmid C, Jamieson D, Lau J . Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007; 21(5):607-15. DOI: 10.1097/QAD.0b013e32802ef2f6. View

19.

Zash R, Holmes L, Diseko M, Jacobson D, Brummel S, Mayondi G . Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019; 381(9):827-840. PMC: 6995896. DOI: 10.1056/NEJMoa1905230. View

20.

Eckard A, Kirk S, Hagood N . Contemporary Issues in Pregnancy (and Offspring) in the Current HIV Era. Curr HIV/AIDS Rep. 2019; 16(6):492-500. PMC: 6938215. DOI: 10.1007/s11904-019-00465-2. View